Trial Profile

Phase II/III trial of UB-612 vaccine

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 17 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UB 612 (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Sponsors United Biomedical

Most Recent Events

17 Sep 2020 New trial record
23 Aug 2020 According to United Biomedical, Inc. (UBI) media release, the company has proposed subsidies to the US Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI) for conducting human clinical trials in the United States. The application is expected to start this trial in USA by the end of this year based on the results of Taiwan's Phase I dose-escalation trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com